Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News
Mason Two Crow, 22, first came to the Retina Foundation in 2003 with a diagnosis of X-linked retinoschisis, a rare genetic condition affecting the retina. Two years ago he came in for a follow-up appointment where he learned that he had the opportunity to be one of the very first to ever be enrolled in a gene therapy trial for his rare eye disease. Mason gives credit to the research scientists at the Retina Foundation for gifting him with the hope that a cure for X-linked retinoschisis may be on the horizon. Click here to read more of Mason’s incredible story on www.dallasnews.com.

Related Articles
Mark Pennesi, M.D., Ph.D., FARVO, Director of Ophthalmic Genetics, celebrates first year with the Retina Foundation The Effectiveness of Therapeutic Drugs for AMD in the Laboratory Retina Foundation 20/20 Video Research Updates Age-Related Macular Degeneration Happenings at the Foundation Investigating Reading Readiness in Preschool Children with Amblyopia (Lazy Eye)